Impact of Fertility Concerns on Tamoxifen Initiation and Persistence

Journal of the National Cancer Institute

Volumn 107, Issue 10, 2015, Pages

  Llarena, Natalia C ^a   Estevez, Samantha L ^a   Tucker, Susan L ^b   Jeruss, Jacqueline S ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; DRUG WITHDRAWAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FEMALE FERTILITY; FERTILITY PRESERVATION; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; PARTIAL MASTECTOMY; PREMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; SMOKING; SURVIVOR; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMICALLY INDUCED; DRUG ADMINISTRATION; INFERTILITY, FEMALE; MEDICATION COMPLIANCE; PREVENTION AND CONTROL; PSYCHOLOGY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DRUG ADMINISTRATION SCHEDULE; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; INFERTILITY, FEMALE; MEDICATION ADHERENCE; NEOPLASM RECURRENCE, LOCAL; PREMENOPAUSE; RISK FACTORS; TAMOXIFEN;

EID: 84944682621     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv202     Document Type: Article

References (74)

1. Cruciani L, Romero R, Vaisbuch E, et al. Pentraxin 3 in amniotic fluid: a novel association with intra-amniotic infection and inflammation. J Perinat Med. 2010;38(2):161-171.
2. Gadducci A, Cosio S, Genazzani AR. Ovarian function and childbearing issues in breast cancer survivors. Gynecol Endocrinol. 2007;23(11):625-631.
3. Fleischer RT, Vollenhoven BJ, Weston GC. The effects of chemotherapy and radiotherapy on fertility in premenopausal women. Obstet Gynecol Surv. 2011;66(4):248-254.
4. Lo Presti A, Ruvolo G, Gancitano RA, et al. Ovarian function following radiation and chemotherapy for cancer. Eur J Obstet Gynecol Reprod Biol. 2004;113(Suppl 1):S33-S40.
5. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718-1729.
6. Ruddy KJ, Gelber SI, Tamimi RM, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol. 2014;32(11):1151-1156.
7. Howard-Anderson J, Ganz PA, Bower JE, et al. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104(5):386-405.
8. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22(20):4174-4183.
9. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351(9114):1451-1467.
10. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-816.
11. Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21(4):602-606.
12. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120-4128.
13. Barron TI, Connolly R, Bennett K, et al. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer. 2007;109(5):832-839.
14. Cunha GR, Taguchi O, Namikawa R, et al. Teratogenic effects of clomiphene, tamoxifen, and diethylstilbestrol on the developing human female genital tract. Hum Pathol. 1987;18(11):1132-1143.
15. Braems G, Denys H, De Wever O, et al. Use of tamoxifen before and during pregnancy. Oncologist. 2011;16(11):1547-1551.
16. Female age-related fertility decline. Committee Opinion No. 589. Fertil Steril. 2014;101(3):633-634.
17. Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006;24(7):1045-1051.
18. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684.
19. Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17(8):2365-2370.
20. Colleoni M, Rotmensz N, Peruzzotti G, et al. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol. 2006;17(10):1497-1503.
21. Abusief ME, Missmer SA, Ginsburg ES, et al. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. 2010;116(4):791-798.
22. Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107-118.
23. Lin JH, Zhang SM, Manson JE. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev Res (Phila). 2011;4(9):1360-1365.
24. http://www.ibcsg.org/Public/Health-Professionals/Open-Trials/ibcsg-48-14-positive/Pages/IBCSG48-14POSITIVE.aspx.
25. Yen TW, Hunt KK, Mirza NQ, et al. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer. 2004;100(5):942-949.
26. Nakhlis F, Lazarus L, Hou N, et al. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma. J Am Coll Surg. 2005;201(5):688-694.
27. Fink AK, Gurwitz J, Rakowski W, et al. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2004;22(16):3309-3315.
28. Lash TL, Fox MP, Westrup JL, et al. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99(2):215-220.
29. Lee TH. The word that shall not be spoken. N Engl J Med. 2013;369(19):1777-1779.
30. Fowler FJ Jr, Gerstein BS, Barry MJ. How patient centered are medical decisions?: Results of a national survey. JAMA Intern Med. 2013;173(13):1215-1221.
31. Committee Opinion No. 601: Tamoxifen and uterine cancer. Obstet Gynecol. 2014;123(6):1394-1397.
32. Zhan M, Flaws JA, Gallicchio L, et al. Profiles of tamoxifen-related side effects by race and smoking status in women with breast cancer. Cancer Detect Prev. 2007;31(5):384-390.
33. Land SR, Cronin WM, Wickerham DL, et al. Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial. Cancer Prev Res (Phila). 2011;4(9):1393-1400.
34. Decensi A, Maisonneuve P, Rotmensz N, et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation. 2005;111(5):650-656.
35. Biglia N, Torta R, Roagna R, et al. Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. Maturitas. 2005;52(1):78-85.
36. Kimmick GG, Lovato J, McQuellon R, et al. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J. 2006;12(2):114-122.
37. Bourque F, Karama S, Looper K, et al. Acute tamoxifen-induced depression and its prevention with venlafaxine. Psychosomatics. 2009;50(2):162-165.
38. Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med. 2009;360(9):902-911.
39. Bedoschi G, Oktay K. Current approach to fertility preservation by embryo cryopreservation. Fertil Steril. 2013;99(6):1496-1502.
40. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013;99(1):37-43.
41. Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923-932.
42. Blumenfeld Z, Katz G, Evron A. 'An ounce of prevention is worth a pound of cure': The case for and against GnRH-agonist for fertility preservation. Ann Oncol. 2014;25(9):1719-1728.
43. Moore HC, Unger JM, Phillips KA. Phase III trial (Prevention of Early Menopause Study (POEMS)-SWOG S0230) of LHRH analog during chemotherapy to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance) ASCO Annual Meeting. J Clin Oncol. 2014;32(5s).
44. Gerber B, Ortmann O. Prevention of Early Menopause Study (POEMS): is it possible to preserve ovarian function by gonadotropin releasing hormone analogs (GnRHa)? Arch Gynecol Obstet. 2014;290(6):1051-1053.
45. Levine JM, Kelvin JF, Quinn GP, et al. Infertility in reproductive-age female cancer survivors. Cancer. 2015;121(10):1532-1539.
46. Peres J. New hope for young breast cancer patients. J Natl Cancer Inst. 2014;106(9):dju308 doi:10.1093/jnci/dju308.
47. National Comprehensive Cancer Network Guidelines Version 2.2105, Adolescent and Young Adult Oncology.
48. Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500-2510.
49. Llarena NC, Jeruss JS. Fertility communication to high-risk patients. In: Woodruff TK, Clayman ML, Waimey KE (ed). Oncofertility communications: sharing information and building relationships across disciplines: Springer; 2014, 61-72.
50. Gradishar WJ, Hellmund R. A rationale for the reinitiation of adjuvant tamoxifen therapy in women receiving fewer than 5 years of therapy. Clin Breast Cancer. 2002;2(4):282-286.
51. Delozier T, Switsers O, Genot JY, et al. Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial). Ann Oncol. 2000;11(5):515-519.
52. Love RR, Olsen MR, Havighurst TC. Delayed adjuvant tamoxifen in postmenopausal women with axillary node-negative breast cancer: mortality over 10 years. J Natl Cancer Inst. 1999;91(13):1167-1168.
53. Gelber S, Coates AS, Goldhirsch A, et al. Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol. 2001;19(6):1671-1675.
54. Sutton R, Buzdar AU, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer. 1990;65(4):847-850.
55. Merkel DE. Pregnancy and breast cancer. Semin Surg Oncol. 1996;12(5):370-375.
56. Malamos NA, Stathopoulos GP, Keramopoulos A, et al. Pregnancy and offspring after the appearance of breast cancer. Oncology. 1996;53(6):471-475.
57. Moore HC, Foster RS Jr. Breast cancer and pregnancy. Semin Oncol. 2000;27(6):646-653.
58. von Schoultz E, Johansson H, Wilking N, et al. Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol. 1995;13(2):430-434.
59. Kroman N, Jensen MB, Melbye M, et al. Should women be advised against pregnancy after breast-cancer treatment? Lancet. 1997;350(9074):319-322.
60. Velentgas P, Daling JR, Malone KE, et al. Pregnancy after breast carcinoma: outcomes and influence on mortality. Cancer. 1999;85(11):2424-2432.
61. Surbone A, Petrek JA. Pregnancy after breast cancer. The relationship of pregnancy to breast cancer development and progression. Crit Rev Oncol Hematol. 1998;27(3):169-178.
62. Lethaby AE, O'Neill MA, Mason BH, et al. Overall survival from breast cancer in women pregnant or lactating at or after diagnosis. Auckland Breast Cancer Study Group. Int J Cancer. 1996;67(6):751-755.
63. Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: "healthy mother effect". Am J Obstet Gynecol. 1994;170(3):818-823.
64. Cooley A, Matthews L, Zelivianski S, et al. Effect of infertility treatment and pregnancy-related hormones on breast cell proliferation in vitro. Hum Reprod. 2012;27(1):146-152.
65. Boukaidi SA, Cooley A, Hardy A, et al. Impact of infertility regimens on breast cancer cells: follicle-stimulating hormone and luteinizing hormone lack a direct effect on breast cell proliferation in vitro. Fertil Steril. 2012;97(2):440-444.
66. Sergentanis TN, Diamantaras AA, Perlepe C, et al. IVF and breast cancer: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(1):106-123.
67. Jeruss JS. Discussing fertility preservation with breast cancer patients. Cancer Treat Res. 2010;156:461-466.
68. Quinn GP, Vadaparampil ST, Lee JH, et al. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol. 2009;27(35):5952-5957.
69. Duffy CM, Allen SM, Clark MA. Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy. J Clin Oncol. 2005;23(4):766-773.
70. Woodruff TK. The Oncofertility Consortium-addressing fertility in young people with cancer. Nat Rev Clin Oncol. 2010;7(8):466-475.
71. Smith K, Efymow B, Gracia, C. Patient navigation and coordination of care for the oncofertility patient: a practical guide. In: Woodruff TK, Gracia C, (ed). Oncofertility Medical Practice. New York: Springer; 2012, 175-185.
72. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917-2931.
73. Wang CJ, Yuen LT, Lee CL, et al. Laparoscopic-assisted vaginal subtotal hysterectomy. J Laparoendosc Adv Surg Tech A. 2005;15(1):33-37.
74. Johnson RH, Kroon L. Optimizing fertility preservation practices for adolescent and young adult cancer patients. J Natl Compr Canc Netw. 2013;11(1):71-77.